
Merck & Co., Inc.
MRK
Updated: 23/09/2026, 04:10:48
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
No summaries found.
The original document can be viewed now. Detailed facts and exposure relationships will appear after the separate extraction job completes.
- Share price
- $150.92
- Market cap
- $372.73B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Robert Davis
- Employees
- 74,000
- IPO date
- 13/01/1978
- Beta
- 0.226
- Last dividend
- $0.00
- Day range
- $148.04 – $153.57
- 52-week range
- $77.58 – $156.92
- 1-day performance
- 0.95%
- 1-year performance
- 94.53%
- Current drawdown (1Y)
- -3.83%
- CIK
- 0000310158
- CUSIP
- 58933Y105
- ISIN
- US58933Y1055
- Created
- 07/12/2025, 05:19:32
- Last update
- 23/09/2026, 04:10:48
Track Merck & Co., Inc. with an AI analyst
See which prediction-market events move MRK, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
Zacks Investment Research • STOCK • 12/06/2026, 12:31:04
Merck Animal Health to Acquire TARGAN
Business Wire • STOCK • 11/06/2026, 08:45:00
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
Zacks Investment Research • STOCK • 10/06/2026, 11:42:36
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 16:22:17
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Business Wire • STOCK • 08/06/2026, 18:30:00
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
24/7 Wall Street • STOCK • 07/06/2026, 11:30:55
Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise
Seeking Alpha • STOCK • 05/06/2026, 14:25:36
Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for Investors
Zacks Investment Research • STOCK • 05/06/2026, 12:31:20
Merck & Co., Inc. (MRK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 04/06/2026, 16:52:54
Merck's Calderasib Gets FDA's Breakthrough Therapy Tag for NSCLC
Zacks Investment Research • STOCK • 01/06/2026, 16:00:28
Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?
Zacks Investment Research • STOCK • 29/05/2026, 13:11:11
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
Business Wire • STOCK • 29/05/2026, 08:45:00